Corvus Pharmaceuticals IncNASDAQ:CRVS
- LAST PRICE8.9300
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots8.8600/ 5
- Ask / Lots9.5000/ 1
- Open / Previous Close--- / 8.9300
- Day Range---
- 52 Week Range
- Volume14
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CRVS |
|---|---|---|
| 09:32 ET | 4302 | 9.01 |
| 09:33 ET | 971 | 9.1 |
| 09:35 ET | 1400 | 8.955 |
| 09:37 ET | 350 | 9.02 |
| 09:39 ET | 12881 | 9.095 |
| 09:42 ET | 1000 | 9.14 |
| 09:44 ET | 2866 | 9.057 |
| 09:46 ET | 3217 | 8.995 |
| 09:48 ET | 1400 | 9.06 |
| 09:50 ET | 1812 | 9.045 |
| 09:51 ET | 200 | 9.04 |
| 09:53 ET | 4749 | 8.995 |
| 09:55 ET | 6056 | 8.99 |
| 09:57 ET | 2961 | 8.98 |
| 10:00 ET | 1500 | 9.025 |
| 10:02 ET | 100 | 9.04 |
| 10:04 ET | 1600 | 9.05 |
| 10:06 ET | 14090 | 9.11 |
| 10:08 ET | 100 | 9.09 |
| 10:09 ET | 2891 | 9.09 |
| 10:11 ET | 800 | 9.1 |
| 10:13 ET | 8811 | 9.145 |
| 10:18 ET | 7648 | 9.16 |
| 10:20 ET | 900 | 9.19 |
| 10:22 ET | 1900 | 9.2 |
| 10:24 ET | 865 | 9.2 |
| 10:26 ET | 800 | 9.18 |
| 10:27 ET | 6108 | 9.19 |
| 10:29 ET | 1502 | 9.19 |
| 10:31 ET | 4192 | 9.155 |
| 10:33 ET | 2012 | 9.155 |
| 10:36 ET | 3000 | 9.19 |
| 10:38 ET | 2555 | 9.215 |
| 10:40 ET | 2612 | 9.26 |
| 10:42 ET | 1817 | 9.25 |
| 10:44 ET | 300 | 9.22 |
| 10:45 ET | 1100 | 9.25 |
| 10:47 ET | 935 | 9.26 |
| 10:49 ET | 700 | 9.22 |
| 10:51 ET | 1618 | 9.3187 |
| 10:54 ET | 500 | 9.24 |
| 10:56 ET | 400 | 9.285 |
| 10:58 ET | 1400 | 9.25 |
| 11:00 ET | 2944 | 9.295 |
| 11:02 ET | 2110 | 9.27 |
| 11:03 ET | 2550 | 9.295 |
| 11:05 ET | 4303 | 9.3505 |
| 11:07 ET | 1530 | 9.33 |
| 11:09 ET | 1325 | 9.32 |
| 11:12 ET | 1300 | 9.2904 |
| 11:14 ET | 390 | 9.29 |
| 11:16 ET | 3553 | 9.26 |
| 11:18 ET | 6487 | 9.22 |
| 11:20 ET | 4425 | 9.24 |
| 11:21 ET | 310 | 9.26 |
| 11:23 ET | 12242 | 9.265 |
| 11:25 ET | 6658 | 9.245 |
| 11:27 ET | 8322 | 9.25 |
| 11:30 ET | 900 | 9.26 |
| 11:32 ET | 600 | 9.23 |
| 11:34 ET | 1600 | 9.3 |
| 11:36 ET | 640 | 9.315 |
| 11:38 ET | 3660 | 9.27 |
| 11:39 ET | 4000 | 9.285 |
| 11:41 ET | 2177 | 9.264 |
| 11:43 ET | 5463 | 9.25 |
| 11:45 ET | 1707 | 9.27 |
| 11:48 ET | 15905 | 9.23 |
| 11:50 ET | 800 | 9.235 |
| 11:52 ET | 200 | 9.2 |
| 11:54 ET | 876 | 9.26 |
| 11:56 ET | 600 | 9.26 |
| 11:57 ET | 1387 | 9.3 |
| 11:59 ET | 3159 | 9.29 |
| 12:01 ET | 7300 | 9.315 |
| 12:03 ET | 400 | 9.315 |
| 12:06 ET | 1565 | 9.3 |
| 12:08 ET | 1850 | 9.3 |
| 12:12 ET | 900 | 9.3 |
| 12:14 ET | 1148 | 9.28 |
| 12:15 ET | 200 | 9.265 |
| 12:17 ET | 500 | 9.26 |
| 12:19 ET | 3151 | 9.245 |
| 12:21 ET | 375 | 9.2392 |
| 12:24 ET | 1402 | 9.21 |
| 12:26 ET | 1696 | 9.19 |
| 12:28 ET | 150 | 9.22 |
| 12:30 ET | 3936 | 9.17 |
| 12:32 ET | 200 | 9.16 |
| 12:33 ET | 437 | 9.19 |
| 12:35 ET | 1100 | 9.22 |
| 12:37 ET | 716 | 9.19 |
| 12:39 ET | 600 | 9.18 |
| 12:42 ET | 518 | 9.17 |
| 12:44 ET | 1264 | 9.19 |
| 12:46 ET | 1774 | 9.17 |
| 12:48 ET | 1700 | 9.16 |
| 12:50 ET | 200 | 9.13 |
| 12:51 ET | 2100 | 9.18 |
| 12:53 ET | 750 | 9.13 |
| 12:55 ET | 950 | 9.13 |
| 12:57 ET | 600 | 9.155 |
| 01:00 ET | 2997 | 9.12 |
| 01:02 ET | 500 | 9.1 |
| 01:04 ET | 100 | 9.1 |
| 01:06 ET | 500 | 9.15 |
| 01:08 ET | 800 | 9.13 |
| 01:09 ET | 3233 | 9.13 |
| 01:11 ET | 1005 | 9.115 |
| 01:13 ET | 2885 | 9.12 |
| 01:15 ET | 405 | 9.17 |
| 01:18 ET | 3538 | 9.1311 |
| 01:20 ET | 1647 | 9.12 |
| 01:22 ET | 100 | 9.135 |
| 01:24 ET | 3582 | 9.1215 |
| 01:26 ET | 900 | 9.115 |
| 01:29 ET | 1400 | 9.14 |
| 01:31 ET | 1113 | 9.11 |
| 01:33 ET | 3746 | 9.1 |
| 01:36 ET | 1292 | 9.105 |
| 01:38 ET | 1115 | 9.12 |
| 01:40 ET | 2100 | 9.12 |
| 01:42 ET | 1200 | 9.115 |
| 01:44 ET | 316 | 9.1 |
| 01:45 ET | 11135 | 9.035 |
| 01:47 ET | 1070 | 9.04 |
| 01:49 ET | 7651 | 9.05 |
| 01:51 ET | 100 | 9.055 |
| 01:54 ET | 958 | 9.04 |
| 01:56 ET | 1300 | 9.045 |
| 01:58 ET | 454 | 9.07 |
| 02:00 ET | 802 | 9.08 |
| 02:02 ET | 2396 | 9.08 |
| 02:03 ET | 609 | 9.085 |
| 02:05 ET | 1050 | 9.105 |
| 02:07 ET | 700 | 9.12 |
| 02:09 ET | 397 | 9.13 |
| 02:12 ET | 1000 | 9.13 |
| 02:14 ET | 678 | 9.12 |
| 02:16 ET | 222 | 9.14 |
| 02:18 ET | 1037 | 9.125 |
| 02:20 ET | 635 | 9.1318 |
| 02:21 ET | 201 | 9.1001 |
| 02:23 ET | 532 | 9.1 |
| 02:25 ET | 500 | 9.09 |
| 02:30 ET | 4070 | 9.13 |
| 02:32 ET | 6797 | 9.13 |
| 02:34 ET | 302 | 9.11 |
| 02:36 ET | 731 | 9.1 |
| 02:38 ET | 1531 | 9.12 |
| 02:39 ET | 300 | 9.12 |
| 02:41 ET | 2330 | 9.075 |
| 02:43 ET | 1779 | 9.06 |
| 02:45 ET | 560 | 9.11 |
| 02:48 ET | 1310 | 9.1 |
| 02:50 ET | 2724 | 9.06 |
| 02:54 ET | 1501 | 9.03 |
| 02:56 ET | 2100 | 9.06 |
| 02:57 ET | 1450 | 9.07 |
| 02:59 ET | 850 | 9.08 |
| 03:01 ET | 1200 | 9.05 |
| 03:03 ET | 700 | 9.01 |
| 03:06 ET | 31064 | 8.9409 |
| 03:08 ET | 2420 | 8.965 |
| 03:10 ET | 824 | 8.965 |
| 03:12 ET | 1180 | 9 |
| 03:14 ET | 1400 | 8.97 |
| 03:15 ET | 100 | 8.98 |
| 03:17 ET | 3321 | 8.935 |
| 03:19 ET | 1159 | 8.92 |
| 03:21 ET | 300 | 8.92 |
| 03:24 ET | 1463 | 8.935 |
| 03:26 ET | 2136 | 8.92 |
| 03:28 ET | 1404 | 8.9 |
| 03:30 ET | 10287 | 8.93 |
| 03:32 ET | 3782 | 8.945 |
| 03:33 ET | 5059 | 8.96 |
| 03:35 ET | 2600 | 8.975 |
| 03:37 ET | 5300 | 8.995 |
| 03:39 ET | 2753 | 9.01 |
| 03:42 ET | 9240 | 8.99 |
| 03:44 ET | 4705 | 8.98 |
| 03:46 ET | 1500 | 9.01 |
| 03:48 ET | 5693 | 9.01 |
| 03:50 ET | 4350 | 9.01 |
| 03:51 ET | 9043 | 9 |
| 03:53 ET | 5050 | 9.02 |
| 03:55 ET | 9477 | 9 |
| 03:57 ET | 16884 | 9 |
| 04:00 ET | 79137 | 8.93 |
Nov 14, 2024
Corvus Pharmaceuticals Announces New Preclinical Data Highlighting Potential of Soquelitinib to Treat Systemic Sclerosis, from 10:01AM ET on Thursday Nov 14, 2024 by Dow Jones
10:01AM ET on Thursday Nov 14, 2024 by Dow Jones
Nov 13, 2024
DJ Corvus Pharmaceuticals Is Maintained at Outperform by Oppenheimer, from 9:51AM ET on Wednesday Nov 13, 2024 by Dow Jones
9:51AM ET on Wednesday Nov 13, 2024 by Dow Jones
Nov 12, 2024
*DJ Corvus Pharmaceuticals 3Q Loss/Shr 60c >CRVS, from 4:01PM ET on Tuesday Nov 12, 2024 by Dow Jones
4:01PM ET on Tuesday Nov 12, 2024 by Dow JonesCorvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results, from 4:01PM ET on Tuesday Nov 12, 2024 by Dow Jones
4:01PM ET on Tuesday Nov 12, 2024 by Dow Jones
Nov 9, 2024
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Corvus Pharmaceuticals Inc | 575.1M | -9.6x | --- |
Savara Inc | 576.6M | -7.7x | --- |
Sana Biotechnology Inc | 582.7M | -1.8x | --- |
Third Harmonic Bio Inc | 561.9M | -12.8x | --- |
Tourmaline Bio Inc | 590.0M | -14.1x | --- |
Mind Medicine (MindMed) Inc | 554.4M | -3.8x | --- |
Company Information
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of ITK inhibition as a new approach to immunotherapy for a range of cancer and immune diseases. Its lead product candidate is soquelitinib, a selective, covalent inhibitor of ITK (interleukin 2 inducible T cell kinase) and is in a multi-center Phase 1/1b clinical trial in patients with various recurrent, malignant T cell lymphomas. Soquelitinib is designed to inhibit the proliferation of certain malignant T cells. Its second product candidate, ciforadenant, is an oral, small molecule antagonist of the A2A receptor for adenosine designed to disable a tumor’s ability to subvert attack by the immune system by blocking the binding of immunosuppressive adenosine in the tumor microenvironment to the A2A receptor. The Company’s third product candidate is mupadolimab, a humanized monoclonal antibody that is designed to react with a specific site on CD73.
Contact Information
- Headquarters
- 863 Mitten Rd Ste 102BURLINGAME, CA, United States 94010-1311
- Phone
- 650-900-4520
- Fax
- 302-655-5049
Executives
- Chairman of the Board
- Richard Miller
- Chief Financial Officer
- Leiv Lea
- Senior Vice President, Chief Business Officer
- Jeffrey Arcara
- Senior Vice President - Pharmaceutical Development
- William Jones
- Independent Director
- Ian Clark
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $575.1M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 64.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.05 |
EPS | $-0.93 |
Book Value | $0.79 |
P/E Ratio | -9.6x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
